The first disease due to mitochondrial dysfunction was described in 1962 by Luft and coworkers in the Journal of Clinical Investigation. Since then, there has been a dramatic increase in interest and research into the structure and function of the mitochondria and in the knowledge of their metabolic significance and causal relationships with numerous health impairments. Depending on their energy demand, organs are affected to differing degrees by an impairment of mitochondrial function. The heart and skeletal muscle cells, brain, and retina, therefore, show a much more pronounced response to mitochondrial insufficiency.

Mitochondrial dysfunction is characterized by reduced  ATP synthetic performance and an associated energy deficit on the one hand, and by increased oxidative stress and greater mutation of mitochondrial DNA (mtDNA) on the other. This leads to the functional insufficiency of the affected cells and tissues and to their premature death and mutagenic change. Muscle weakness, rapid muscle fatigability, poor training capacity, or muscle pain on exercise and even at rest can be initial signs of mitochondrial dysfunction in young patients.

Mitochondrial diseases arising from mtDNA mutations have a prevalence of approximately 10 – 20 per 100,000. Today, more than 200 mutations of mtDNA are known. Besides the diseases caused by a hereditary genetic defect in the mtDNA, however, an increasing number of lifetime acquired diseases are now being seen as causally associated with mitochondrial dysfunction. These include neurodegenerative diseases such as Alzheimer’s or Parkinson’s disease, cardiovascular diseases, diabetes mellitus, or malignant conditions.

To function properly, these antioxidant systems need the bioactive substances of the kind contained in EnzymeYeast Cells Dr. Wolz®. Human genetic material is 70 %identical to the genetic material of the enzyme yeast cells. All the ingredients of Enzyme Yeast Cells Dr. Wolz®, therefore, show good bioavailability.

 

WE RECOMMEND

RELATED ARTICLES

Meniu